HomeCompareNXSCF vs DIVO

NXSCF vs DIVO: Dividend Comparison 2026

NXSCF yields 10095.00% · DIVO yields 6.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NXSCF wins by $60522276252191552.00M in total portfolio value
10 years
NXSCF
NXSCF
● Live price
10095.00%
Share price
$0.00
Annual div
$0.10
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$60522276252191552.00M
Annual income
$59,365,457,623,754,850,000,000.00
Full NXSCF calculator →
DIVO
DIVO
● Live price
6.49%
Share price
$44.85
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$981.68
Full DIVO calculator →

Portfolio growth — NXSCF vs DIVO

📍 NXSCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNXSCFDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NXSCF + DIVO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NXSCF pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NXSCF
Annual income on $10K today (after 15% tax)
$858,075.00/yr
After 10yr DRIP, annual income (after tax)
$50,460,638,980,191,620,000,000.00/yr
DIVO
Annual income on $10K today (after 15% tax)
$552.00/yr
After 10yr DRIP, annual income (after tax)
$834.43/yr
At 15% tax rate, NXSCF beats the other by $50,460,638,980,191,620,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NXSCF + DIVO for your $10,000?

NXSCF: 50%DIVO: 50%
100% DIVO50/50100% NXSCF
Portfolio after 10yr
$30261138126095776.00M
Annual income
$29,682,728,811,877,424,000,000.00/yr
Blended yield
98.09%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NXSCF buys
0
DIVO buys
0
No recent congressional trades found for NXSCF or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNXSCFDIVO
Forward yield10095.00%6.49%
Annual dividend / share$0.10$2.91
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$60522276252191552.00M$30.7K
Annual income after 10y$59,365,457,623,754,850,000,000.00$981.68
Total dividends collected$60445311406050536.00M$8.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: NXSCF vs DIVO ($10,000, DRIP)

YearNXSCF PortfolioNXSCF Income/yrDIVO PortfolioDIVO Income/yrGap
1← crossover$1,020,200$1,009,500.00$11,349$649.42+$1.01MNXSCF
2$97,343,193$96,251,579.44$12,833$688.83+$97.33MNXSCF
3$8,687,260,875$8,583,103,657.69$14,459$727.90+$8687.25MNXSCF
4$725,171,452,913$715,876,083,776.83$16,238$766.49+$725171.44MNXSCF
5$56,624,484,726,557$55,848,551,271,940.71$18,179$804.47+$56624484.71MNXSCF
6$4,136,189,552,978,259$4,075,601,354,320,842.00$20,293$841.71+$4136189552.96MNXSCF
7$282,655,809,165,117,900$278,230,086,343,431,170.00$22,591$878.14+$282655809165.10MNXSCF
8$18,072,047,576,372,183,000$17,769,605,860,565,506,000.00$25,087$913.65+$18072047576372.16MNXSCF
9$1,081,138,905,081,034,700,000$1,061,801,814,174,316,400,000.00$27,791$948.18+$1081138905081034.75MNXSCF
10$60,522,276,252,191,556,000,000$59,365,457,623,754,850,000,000.00$30,718$981.68+$60522276252191552.00MNXSCF

NXSCF vs DIVO: Complete Analysis 2026

NXSCFStock

Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia.

Full NXSCF Calculator →

DIVOETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this NXSCF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NXSCF vs SCHDNXSCF vs JEPINXSCF vs ONXSCF vs KONXSCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.